Research progress in diagnosis and treatment of radioiodine-refractory differentiated thyroid cancer

林岩松; 杨　雪

doi:10.19401/j.cnki.1007-3639.2017.06.008

您当前的位置：

首页 >

文章列表页 >

Research progress in diagnosis and treatment of radioiodine-refractory differentiated thyroid cancer

更新时间：2025-12-31

- Research progress in diagnosis and treatment of radioiodine-refractory differentiated thyroid cancer
- China Oncology Vol. 27, Issue 6, Pages: 442-450(2017)
- 作者机构：
  
  中国医学科学院北京协和医院核医学科,北京,100730
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2017.06.008
  CLC：
- Published Online：26 July 2017，
  
  Published：26 July 2017
- 稿件说明：
移动端阅览
林岩松,杨　雪. 碘难治性甲状腺癌的诊治进展[J]. 中国癌症杂志, 2017, 27(6): 442-450.

林岩松, 杨　雪. Research progress in diagnosis and treatment of radioiodine-refractory differentiated thyroid cancer[J]. China Oncology, 2017, 27(6): 442-450.
林岩松,杨　雪. 碘难治性甲状腺癌的诊治进展[J]. 中国癌症杂志, 2017, 27(6): 442-450. DOI： 10.19401/j.cnki.1007-3639.2017.06.008.

林岩松, 杨　雪. Research progress in diagnosis and treatment of radioiodine-refractory differentiated thyroid cancer[J]. China Oncology, 2017, 27(6): 442-450. DOI： 10.19401/j.cnki.1007-3639.2017.06.008.

摘要

多数分化型甲状腺癌(differentiated thyroid cancer，DTC)经过规范的手术、选择性131I治疗及促甲状腺激素抑制治疗后预后良好，然而，仍有部分转移性DTC的患者在早期或131I治疗过程中失去了摄碘能力发展为碘难治性DTC(radioiodine-refractory DTC，RAIR-DTC)。RAIR-DTC病情进展快，死亡率高，为这些患者寻找有效的治疗手段一直是甲状腺癌领域研究的热点。该文对碘难治性甲状腺癌的诊断及治疗进展进行综述，为及早识别这些患者，并为其他可能获益的治疗手段如靶向治疗及放疗等的早期干预争取时间。

Abstract

Surgery

selective radioiodine therapy and thyroid stimulating hormone suppressive therapy are the standard treatment modalities for differentiated thyroid cancer (DTC). After therapy

most DTC patients could get good prognosis. However

some patients with distant metastasis lose the ability to concentrate radioiodine at early time or during the treatment

and develop radioiodine-refractory DTC (RAIR-DTC). These patients progress quickly and have high mortality. Looking for effective treatments for these patients has been the hot spot in research of thyroid carcinoma. In this paper

we summarized the recent advances in the diagnosis and treatment of RAIR-DTC

hoping to early identify these patients and buy time for early intervention of other possible beneficial treatments such as targeted therapy and radiotherapy.

关键词

Keywords

references

Views

3702

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Advances in basic research, clinical diagnosis and treatment of thyroid cancer in 2022

Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: advances in surgical treatment of differentiated thyroid cancer

Research progress and future perspectives of anticancer drug-induced interstitial lung disease/pneumonia in gastric cancer

Survival and cause-of-death analysis of 55 thousand thyroid cancer cases in China from a large single institution hospital-based cancer registry database

Current status and prospect of diagnosis and treatment of bone metastasis of thyroid cancer

Related Author

Ning QU

Yuting WANG

Ben MA

Yu WANG

Qian SHI

Jugao FANG

Xiaoyu GUO

Xiujuan QU

Related Institution

Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University

Department of Medical Oncology, The First Hospital of China Medical University

Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

AI问答

⁰